In a significant development in breast cancer treatment, Swiss pharmaceutical major Roche has received a US Food and Drug Administration (FDA) nod for its new oral breast cancer drug, Wilserdly (giredestrant). The drug is approved for use with everolimus. It is meant for patients with advanced breast cancer whose disease no longer responds to hormone-based treatment.